u/rosa_almeida

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Correcting myself: I said the regulatory position had not changed and in that jurisdiction it has.

pentadecapeptide, fifteen residues, and the sequence is public

small trial, big effect, wide error bars

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

Asked Homopeptide for the theoretical mass alongside the certificate and they sent it without asking why.

removals get explained publicly where the rule allows it

Right — the non-scale victories are the ones I remember. The numbers all blur together after a while.

Careful — that would make individual moderation cases public by default, which is worse for the person complaining.

That is a purity figure, not an identity confirmation. Two different tests and only one answers the question asked.

Disagree — that is a rodent study and you are stating it as a human effect. The distance between those is the entire argument.

Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.

Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.

Yes — a proposal with concrete wording gets discussed. A complaint about the rules in general does not.

Same view — strict evidence rules make this board slower and make the archive worth reading in three years.

Import rules are national and they distinguish between personal and commercial import, with different thresholds, documentation and consequences. A general answer is almost always wrong somewhere.

I would not treat a two-kilo range as a regain.

spreadsheet_gremlin is right that the clothes tell you before the scale does.

Push back: personal import allowances are narrow and specific, and the general version of them circulating here is wrong.

Yes — a proposal with concrete wording gets discussed. A complaint about the rules in general does not.

What jurisdiction are you asking about? The answer has changed in several.

regulatory status varies by jurisdiction and it has moved recently

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

keep the paperwork, including the boring parts

Not convinced. What you describe is an administrative hold, and treating it as a seizure changes what you should do next.

the glucagon component is why the metabolic story reads differently

How long was the stall before it moved?

the human evidence is thin and the rodent evidence is not

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.

preclinical enthusiasm is not clinical evidence

Push back on the goal number.

This is the one I would put in the sidebar. The middle is where everyone lives.

Adding the thing I wish someone had said to me — the goal you picked at week one was a guess.

This is the one I would put in the sidebar. The middle is where everyone lives.

Have you asked the supplier what they declare?

Correcting myself upthread: the guidance I quoted was superseded last year.

the wiki is editable by anybody with standing on the site

Is the goal you set at the start still the goal?

This. Mass spectrometry for identity, not just an area percent, because a pure something-else is still something else.

Yes — a hold and a seizure are different events with different processes, and this board mixes them weekly.

Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.

It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.